Define what the luminescence represents
Clarify whether the reporter measures activation, inhibition, neutralization, pathway response, transcription, or another endpoint. Define timing, cell state, receptor or construct, substrate, reader settings, and concentration units.
Raw luminescence is not automatically proportional to biological effect across its full range. Instrument saturation, substrate kinetics, cell number, cytotoxicity, and background can alter the response.
Use controls that expose different failure modes
Include background and response controls appropriate to the mechanism, plus plate or reference controls for run comparison. A viability or orthogonal control may help distinguish loss of reporter signal from nonspecific cytotoxicity.
Inspect control distributions and positions. Calculate signal window, variability, or Z′ only where the design and intended use make those metrics appropriate; do not apply a universal threshold without justification.
Preserve raw signal when normalizing
Document blank correction, percent activity or inhibition, reference scaling, dual-luciferase normalization, or plate normalization. Retain every raw component and formula so normalized values can be traced.
Normalization can introduce correlation and propagate control variability. Display control behavior beside the fitted test curves rather than treating normalization as a cleanup step.
Fit the response and inspect assay-specific diagnostics
A 4PL or 5PL may summarize EC50, IC50, or relative potency where a sigmoid is appropriate. Review concentration coverage, residuals, asymptotes, slope, replicate variation, convergence, and known biological constraints.
For relative potency, test whether the reference and sample relationship supports the comparison. Report the exact model and any shared or fixed parameters.
Worked example: normalize activation without discarding raw light units
Suppose the background control mean is 8,000 RLU, the maximum-response control mean is 120,000 RLU, and a treated sample measures 64,000 RLU. Background-corrected percent activation is (64,000 − 8,000) ÷ (120,000 − 8,000) × 100 = 50%.
Keep all three raw measurements, the control assignments, the normalization formula, and the 50% derived response. If viability or a second reporter is also used, retain its raw values and calculation as a separate step rather than overwriting the primary signal.
(64,000 − 8,000) ÷ (120,000 − 8,000) × 100 = 50% activationDefine the complete reporter-assay result
Specify the required controls, normalization, curve model, suitability checks, reported results, tables, plots, and instrument-file formats. Test each calculation and decision rule against independently verified expected results.
The report should connect raw luminescence, control behavior, normalization, concentrations, fitted curve, exclusions, diagnostics, and final endpoint so an unexpected result can be investigated without reconstructing the plate by hand.
Frequently asked questions
Is luminescence normalization always required?
No. It depends on assay design and endpoint. Any normalization should have a defined purpose, validated formula, appropriate controls, and retained raw values.
Can Z′ determine whether a potency result is valid?
Z′ describes control separation and variability under a specific design. It does not by itself establish fit adequacy, sample comparability, or reportable potency.